The German biotech company CureVac is denying reports that Trump administration officials attempted to acquire the company.

"There was and there is no takeover offer from the White House or governmental authorities. Neither to the technology nor to CureVac at all as a company," CureVac acting CEO Franz-Werner Haas said on a Tuesday conference call with reporters.

CureVac is in the early stages of developing a coronavirus vaccine. The company hopes to begin testing a vaccine candidate in humans as early as June.

The biotech has also drawn intrigue over recent changes in leadership. CureVac is now on its third CEO within the past seven days. Company leaders called the timing of the CEO switches alongside the Trump administration news reports a "pure coincidence."

Visit Business Insider's homepage for more stories.

The German biotech company working on a coronavirus vaccine has denied reports that the Trump administration made moves to acquire the firm or its research.

CureVac has been shooting down the news reports for several days, and added to the denials in a conference call with investors on Tuesday.

"There was and there is no takeover offer from the White House or governmental authorities. Neither to the technology nor to CureVac at all as a company," CureVac acting CEO Franz-Werner Haas said on a conference call on Tuesday.

CureVac gained widespread attention over the weekend after the German newspaper Welt am Sonntag reported that a Trump administration official offered large sums of money for rights to its vaccine, "but only for the USA."

Read more: Everything you need to know about CureVac, the drugmaker working on a coronavirus vaccine that's at the heart of a Trump-Germany controversy

Adding to the confusion, the company is now on its third CEO within the past seven days.

The first CEO, Daniel Menichella, attended a March 2 White House meeting of pharmaceutical executives. Without CureVac giving a reason at the time, he left the company, effective immediately, on March 11.

"All the speculation, if this has something to do with the rumors around the White House and the visit in the White House or anything like that is wrong," said Friedrich von Bohlen, a prominent shareholder and board member at CureVac. "It is a pure coincidence of things and timelines."

Menichella was replaced by Ingmar Hoerr, the longtime founder and previous CEO of CureVac. But on March 16, just five days into his second tenure as CEO, Hoerr stepped down from the position citing medical reasons. CureVac then installed Haas as acting CEO for the time being.

Bohlen said he did not know how long Hoerr would be on medical leave.

"For how long will that be? Honestly I don't know," Bohlen said Tuesday. "Surely for some time. Don't ask me what some time means."